QLT.CA Profile & Description — QLT Inc
QLT is a biotechnology company engaged in the development and commercialization of ocular products. Co.'s operations consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases caused by retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase gene mutations, which indication includes Leber Congenital Amaurosis and Retinitis Pigmentosa. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.